SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced the appointments of Erle T. Mast and Thomas G. Wiggans as independent directors of the company. In addition, Mr. Mast will serve as chairman of the company’s audit committee, and Mr. Wiggans will serve as a member of the company’s nominating/corporate governance committee. These appointments fill the vacancies on the company’s board of directors created by the resignations of Kenneth M. Cohen and Cam L. Garner, each of whom is a co-founder of the company and served on the board of directors since August 2003. The number of company directors remains at nine, with a seven-member independent majority.
